{
    "organizations": [],
    "uuid": "e21f843ba5239d7d79a664958774c9b8c2357002",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-says-receive/brief-cosmo-pharmaceuticals-says-receives-letter-from-fda-on-methylene-blue-mmx-idUSFWN1SG1H9",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals Says Receives Letter From FDA On Methylene Blue MMX",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - Cosmo Pharmaceuticals NV:\n* RECEIVED A LETTER FROM FDA AS PART OF THEIR ONGOING REVIEW OF COMPANYâ€™S NEW DRUG APPLICATION\n* AGENCY HAS IDENTIFIED DEFICIENCIES * COSMO PHARMACEUTICALS - DEFICIENCIES PRECLUDE CONTINUATION OF DISCUSSION OF LABELING AND POST MARKETING REQUIREMENTS AT THIS TIME Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-09T23:57:00.000+03:00",
    "crawled": "2018-05-10T17:48:09.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "received",
        "letter",
        "fda",
        "part",
        "ongoing",
        "review",
        "company",
        "new",
        "drug",
        "application",
        "agency",
        "identified",
        "deficiency",
        "cosmo",
        "pharmaceutical",
        "deficiency",
        "preclude",
        "continuation",
        "discussion",
        "labeling",
        "post",
        "marketing",
        "requirement",
        "time",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}